RA Capital

Abcuro’s mission is to develop immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by their founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease, together with ex-vivo validation in diseased tissue, has uncovered new approaches to target key compartments of the immune system.

Adcendo is a Danish clinical-stage biotech company headquartered in Copenhagen, dedicated to the development of highly differentiated First-In-Class Antibody-drug conjugates (ADCs) for treatment of solid tumors. In November of 2024, the company announced the closing of a USD 135m series B financing round. With a total sum of USD 240m raised since 2021 and under the leadership of a highly experienced management team, Adcendo is moving forward a growing and highly differentiated pipeline of drug candidates into the clinic.

Adcytherix is a biopharmaceutical firm that specializes in the development of new Antibody Drug Conjugates (ADC) to treat diseases with a high unmet need, including cancer.

AdVia Therapeutics is a venture capital backed, discovery phase, life science company developing new gene therapies to treat genetic diseases for which treatment options are currently lacking. AdVia uses a proprietary discovery and delivery platform to identify and optimize new gene therapy vectors with the greatest potential for therapeutic development.

Ajax Therapeutics develops targeted therapies for hematologic cancers, with a focus on treating myeloproliferative neoplasms through precision drug discovery approaches. The company applies computational chemistry and structural biology to design small-molecule therapies that selectively target disease-driving proteins while minimizing off-target effects. Its research centers on next-generation inhibitors of the JAK2 protein, a key driver of certain blood cancers, using a differentiated mechanism that binds the Type II conformation of the kinase. This approach aims to improve treatment effectiveness and address limitations of existing therapies that provide symptom relief but do not fully suppress disease progression. It integrates discovery, preclinical research, and clinical development within its operating model, enabling continuous refinement of drug candidates based on biological insights and trial data. It collaborates with research institutions and leverages scientific expertise in oncology and molecular medicine to support development efforts.

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. The company is building their transformative engine to identify drug targets and develop a pipeline of antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases. Alchemab Therapeutics was established in 2019 by Uri Laserson and Jane Osbourn in London, England.

Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech investigating novel therapeutics for CLDN1+ cancers. Alentis is the pioneering business in the use of anti-CLDN1 ADCs and antibodies to modify and reverse the progression of certain diseases.

Alpha-9 Oncology is a clinical-stage biotechnology company developing radiopharmaceuticals for solid and hematologic malignancies.

Ambros Therapeutics is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases.

ARS Pharmaceuticals is a stealth pharmaceutical company that developed a novel intranasal epinephrine spray with a unique absorption technology that could be easy to use, convenient, and more reliable for patients and loved ones at risk of severe allergic reactions to food, medications, and insect bites that could lead to life-threatening anaphylaxis.

Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva’s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.